We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on ...

Additionally, we intend to provide the rest of the world with an additional, reliable source of suramin, the accepted standard of care for Stage 1, Trypanosoma Brucei Rhodesiense. We are dedicated to ...

(2025-01-14 | GREY:PXMD) PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions. Stockhouse.com uses cookies on ...

Suramin Medication Information. Learn everything you need to know about Suramin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it.

TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological ...

We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of our efforts, ...

Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a g ...

National. Suramin Reduces Drug Resistance In Mycobacteria, Says Study Strategies to tackle drug-resistant strains include identification of new antibiotics or targeting the bacterial mechanisms ...

PaxMedica's suramin treatment for ASD gains spotlight in analyst report ...

The report comes on the heels of PaxMedica's announcement today that it plans to file a New Drug Application (NDA) next year for PAX-101, its intravenous suramin treatment.